Anirvan Ghosh joins Biogen in executive research post

16 March 2017
biogen-big-1

US biotech major Biogen (Nasdaq: BIIB) has appointed Anirvan Ghosh as senior vice president, research and early development (RED).

Dr Ghosh will lead Biogen’s RED organization in the discovery and development of drug candidates from idea through proof of concept. He will report to Michael Ehlers, executive vice president, head of R&D. Dr Ghosh will begin his service at Biogen in April.

“We are excited to have Anirvan Ghosh join us at Biogen,” said Dr Ehlers, adding: “After an extensive global search, we have found an inspired leader to guide an exceptional Research and Early Development team. Anirvan is an accomplished neuroscientist and industry R&D leader who has delivered multiple novel drug candidates to the clinic.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology